Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in benin

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages 64-72

  Denoeud Ndam, Lise ^a   Clément, Marie Caroline ^a   Briand, Valérie ^a   Akakpo, Jocelyn ^b   Agossou, Videhouenou K ^c   Atadokpédé, Félix ^d   Dossou Gbété, Lucien ^e   Komongui, Didier G ^f   Afangnihoun, Aldric ^g   Girard, Pierre Marie ^h   Zannou, Djimon Marcel ^b   Cot, Michel ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b Universitaire Hubert Koutoukou Maga   (Benin)

^c Universitaire Hubert Koutoukou Maga   (Benin)

^d Service d hépato gastroentérologie Hôpital d Instruction des Armées   (Benin)

^e Clinique Louis Pasteur   (Benin)

^f Hopital de la Mere et de l'Enfant Lagune   (Benin)

^g Centre de Traitement Ambulatoire   (Benin)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Benin; drug tolerance; HIV; malaria; mefloquine; pregnancy

Indexed keywords

COTRIMOXAZOLE; MEFLOQUINE;

ADULT; ARTICLE; BENIN; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EDUCATIONAL STATUS; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NAUSEA; PAIN; PLACENTA MALARIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; VIRUS LOAD; VOMITING;

ADULT; ANTIMALARIALS; BENIN; CHEMOPREVENTION; COHORT STUDIES; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; MALARIA; MEFLOQUINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES;

EID: 84865775813     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182615a58     Document Type: Article

References (33)

1. Dreyfuss ML, Msamanga GI, Spiegelman D, et al. Determinants of low birth weight among HIV-infected pregnant women in Tanzania. Am J Clin Nutr. 2001;74:814-826.
2. Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg. 2003;97:30-35.
3. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93-104.
4. Verhoeff FH, Brabin BJ, Hart CA, et al. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health. 1999;4:5-12.
5. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 2004;71:41-54.
6. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Human immunodeficiency virus seropositivity and malaria as risk factors for third-trimester anemia in asymptomatic pregnant women in western Kenya. Am J Trop Med Hyg. 2001;65:623-630.
7. Ayisi JG, van Eijk AM, ter Kuile FO, et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS. 2003;17:585-594.
8. Kfutwah A, Mary JY, Lemen B, et al. Plasmodium falciparum infection significantly impairs placental cytokine profile in HIV infected Cameroonian women. PLoS One. 2009;4:e8114.
9. Ayisi JG, van Eijk AM, Newman RD, et al. Maternal malaria and perinatal HIV transmission, western Kenya. Emerg Infect Dis. 2004;10:643-652.
10. WHO. WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser. 2000;892:1-74.
11. WHO. Malaria and HIV/AIDS Interactions and Their Implications for Public Health Policies. Report of a Technical Consultation. Geneva, Switzerland: WHO; 2004.
12. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007;297:2603-2616.
13. WHO. A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. Brazzaville, Democratic Republic of Congo: WHO regional office for Africa; 2004.
14. Briand V, Bottero J, Noel H, et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis. 2009;200:991-1001.
15. Aubouy A, Fievet N, Bertin G, et al. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health. 2007;12:886-894.
16. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis. 1994;169:595-603.
17. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948-961.
18. Skinner-Adams TS, McCarthy JS, Gardiner DL, et al. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol. 2008;24:264-271.
19. Uneke CJ, Ogbonna A. Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg. 2009;103:761-767.
20. Akogbeto M, Modiano D, Bosman A. Malaria transmission in the lagoon area of Cotonou, Benin. Parassitologia. 1992;34:147-154.
21. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
22. Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA. 2007;297: 2251-2263.
23. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25:1611-1618.
24. Ekouevi DK, Coffie PA, Ouattara E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2011;56:183-187.
25. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxinepyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813-822.
26. Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148-152.
27. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009;151:149-156.
28. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.
29. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13:367-373.
30. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
31. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
32. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107-2111.
33. El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa-a prospective cohort study. BMC Public Health. 2011;11:88.